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Summary 
N-acetyl-r-leucyl-r-leucyl-t-norleucinal, (LLnL), which inhibits  proteasomes in addition  to 
other proteases, was found to prolong the association of  major histocompatibility complex class I 
molecules with the transporters associated with antigen processing (TAP), and to slow their 
transport out of the endoplasmic reticulum (ER). LLnL induced a reversible accumulation of 
ubiquitinated proteins and changed the spectrum ofpeptides bound by class I molecules. These 
effects can probably be attributed to proteasome inhibition.  Unexpectedly, in the TAP=deft= 
cient cell line. 174, the rate of  intracellular transport of  human histocompatibility leukocyte an- 
tigen  (HLA) A2 was also  reduced by LLnL, and the generation of most HLA-A2-associated 
signal sequence peptides was inhibited. The inhibition of HLA-A2 transport in .174 cells was 
found to be less sensitive to LLnL than in wild-type cells, and a similar difference was found for 
a second protease inhibitor, benzyloxycarbonyl-r-leucyl-r-leucyl-t-phenylalanilal. These data 
suggest that under some conditions such inhibitors can block trimming of peptides by an ER 
peptidase in addition to inhibiting cytosofic peptide generation. 
N 
'ewly synthesized MHC class I heavy chain [~2-micro- 
globulin ([~2m)  1 dimers bind peptides in the endoplas- 
mic reticulum (ER) before their transport to the cell surface. 
The vast majority of  the associated peptides are derived from 
cytosolic proteins. These peptides are transported into the ER 
from the cytosol in an ATP-dependent fashion by'the trans- 
porters associated with antigen processing (TAP; for a review 
see reference 1), which physically associate with peptide- 
free class I-[32m dimers via the TAP. 1 subunit (2-4). Pep- 
tide binding to the  class I  molecules triggers their release 
from TAP, allowing their transport to the cell surface. Cer- 
tain MHC class I alleles also bind peptides derived from the 
signal  sequences  of a small  number of secreted or type I 
transmembrane proteins (5-7). In these cases, peptide load- 
ing is usually, though not always (8), independent of TAP. 
The predominant protease responsible for the generation 
of cytosolically derived, TAP-dependent, class I-associated 
1Abbreviations used in thispaper: 132rn, 132-microglobufin;  endo H, endogly- 
cosidase H; ER, endoplasmic reticulum; 1P-30, the 'y interferon  induct- 
ible protein; LLnL,  N-acetyl-t-leucyl-t-leucyl-t-norleucinal;  RP, reverse 
phase; TAP, transporter associated with antigen processing; TBS, Tris- 
buffered saline; Z-LLF-CHO, benzyloxycarbonyl-tqeucyl-r-leucyl-r- 
phenylalanilal. 
peptides  is  thought  to  be  the  proteasome,  a  large  (20S) 
multisubunit  protease.  The  20S  proteasome  can  degrade 
proteins in vitro, but in vivo it predominantly exists as the 
nucleus of a larger (26S) ATP-dependent complex (9,  10). 
The 26S proteasome is responsible for the degradation of 
ubiquitinated proteins as well as at least one nonubiquiti- 
nated protein, omithine decarboxylase (11,  12).  Two sub- 
units of the proteasome, LMP2 and LMP7, are encoded in 
the MHC  (13).  Mice with targeted disruption of either of 
these genes exhibit some deficiency in CTL development, 
and LMP7-deficient mice exhibit a reduction in expression 
of class I MHC molecules (14,  15). Additionally, treatment 
of antigen-loaded  target  cells  with  proteasome inhibitors 
prevents their recognition by class I-restricted CTL (16). It 
has also  been argued that ubiquitination of cytosolic pro- 
tein antigens  is  important for their recognition by CTL, 
because mutant  cell lines  temperature sensitive for a  key 
step in  ubiquitination  exhibit reduced sensitivity to  CTL 
(17), although this finding is not universally accepted (18). 
One of the inhibitors used by Rock et al.  (16) to impli- 
cate the proteasome in MHC class I peptide generation in 
living  cells  was  the  peptide  aldehyde  N-acetyl-L-leucyl- 
r-leucyl-r-norleucinal  (LLnL),  which  has  recently  been 
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teasome  (19).  The mammalian proteasome has been shown 
to  have  at  least  five  different  proteolytic  activities,  and 
LLnL  inhibits  them  to  varying  degrees  (20,  21).  In  this 
study, we set out to examine the effects of proteasome in- 
hibition  on  TAP-class  I  association  and  on  the  rate  of 
egress of class I-peptide complexes from the ER.  In addi- 
tion to finding anticipated effects, we made the surprising 
observation that transport of HLA-A2 molecules in TAP- 
negative cells was slowed by LLnL, and by a second protea- 
some inhibitor, benzyloxycarbonyl-t-leucyl-L-leucyl-t-phe- 
nylalanilal (Z-LLF-CHO),  and  found  that  the  profile  of 
associated  signal  sequence  peptides  was  also  affected  by 
LLnL.  The  implication of these findings for potential ER 
processing of class I-associated peptides is discussed, 
Materials and Methods 
Cell Lines.  Transfectants of  the HMY2.CIR cell line, C1R.A2, 
C1R.BT,  and CIR.B27  and the TAP-negative mutant cell line 
.174 have been previously described (22,  23).  All cell lines were 
maintained in IMDM  (GIBCO BRL,  Gaithersburg, MD)  with 
5% calf serum (Hyclone Laboratories Inc., Logan, UT) and gen- 
tamicin at 20 p~g/ml. 
Antibodies.  The mAbs 4E  (anti-HLA-B locus), BB7.2  (anti- 
HLA-A2), and  1G12  (antitransferrin receptor) were previously 
described  (24-26).  Affinity-purified anti-TAP.1  rabbit  serum 
R.RING4C  generated against a COOH-terminal peptide from 
TAP.l, (2), and the rat mAb 3B10.7  (anti-class 2) were also pre- 
viously described (27).  Immunoblots were probed with a rabbit 
anti-ubiquitin serum generously provided by Dr. Arthur L. Haas 
(Medical College of Wisconsin, Milwaukee, WI). 
Inhibitors.  The protease inhibitor LLnL or Calpain Inhibitor 1 
was purchased from Calbiochem-Novabiochem Corp. (San Diego, 
CA) and prepared as a 25-raM (100￿  stock solution in DMSO. 
The inhibitor Z-LL-F-CHO was also prepared in DMSO at 25 
mM and was a kind gift from Dr. Marian Orlowski (Mount Sinai 
School of Medicine, New York, NY). 
Metabolic Labeling.  8  X  106  cells were incubated in methio- 
nine-free medium containing 6%  dialyzed FCS  (Hyclone) with 
LLnL at 250  p~M  or the DMSO  solvent as control, for  1 h  at 
37~  The cells were pulse labeled with 0.5 mCi [3SS]methionine 
(ICN Biochemicals, Inc., Costa Mesa, CA) for  15  rain in fresh 
methionine-free medium in the continued presence of LLnL or 
DMSO alone and chased with a 15-fold excess of unlabeled me- 
thionine at 37~  for the indicated times. Labeling was stopped by 
diluting the cells in cold PBS.  For experiments involving reim- 
munoprecipitation, 2 mCi of [3SS]methionine  was used. 
Immunoprecipitations and Endoglycosidase H  Treatment.  Labeled 
cells  were  pelleted and  lysed in  10  mM  Tris,  150  mM  NaCl 
(Tris-buffered saline [TBS]),  pH 7.4,  1% Triton X-100  (Sigma 
Chemical  Co.,  St.  Louis,  MO),  or  1%  digitonin  (Wako  Pure 
Chemical Industries, Ltd., Richmond, VA), containing 0.5 mM 
PMSF, 0.1 mM N-et-tosyl-z-lysyl-chloromethyl  ketone (TLCK), 
and  5.0  mM  iodoacetamide  (IAA).  Postnuclear  supernatants 
were precleared for  1 h  with normal rabbit serum and protein 
A-Sepharose and then incubated with 4E, BB7.2,  or 1G12 and 
protein A-Sepharose for 1 h. Endoglycosidase H  (endo H) diges- 
tions  were  performed  as  described previously  (28).  To  detect 
TAP-associated class I molecules in R.RING4C immunoprecipi- 
tates from digitonin extracts, the protein A beads were heated at 
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100~  for 5 rain in 2% SDS, 2 mM dithiothreitol in TBS, diluted 
10-fold in 1% Triton )(-100 in TBS with 10 mM IAA, and al- 
lowed to incubate at room temperature for 30 rain. After cooling 
to 4~  released class I  heavy chains were precipitated as above 
with 3B10.7 and protein G-Sepharose. 
Immunoblots.  Blots were performed as described (29). Briefly, 
106 cells were lysed in 100 p~l 1% Triton X-100 in TBS as above. 
Postnuclear  supematants  were  diluted  with  reducing  sample 
buffer, separated by a 5-20% gradient SDS-PAGE, and electro- 
blotted onto  an  Immobilon membrane  (Millipore Corp.,  Bed- 
ford, MA). The membrane was blocked for 1 h in PBS contain- 
ing 0.05% Tween 20 and 5% dehydrated milk, rinsed in PBS, and 
incubated overnight at 4~  with the rabbit anti-ubiquitin serum 
diluted in PBS containing Tween 20 and dehydrated milk. Bands 
were visualized with horseradish peroxidase-conjugated second- 
ary  goat  anti-rabbit  IgG  antibody  and  epichemiluminescence 
(ECL) substrate (Amersham Corp., Arlington Heights, IL). 
Analysis of 3H-labeled Class 1-associated Peptides.  Cells  (6-8  ￿ 
105) in log phase growth were washed in PBS and incubated for 1 h 
at 37~  in Leu-free, Lys-free RPMI-1640 (GIBCO BRL) at 107 
cells/ml, supplemented with 3% dialyzed FCS and 10 mM Hepes 
(GIBCO BRL) with or without 25 mM LLnL, added as a 100￿ 
stock.  Control  experiments  contained  equal  concentrations  of 
DMSO  (0.1% vol/vol). 1 mCi each of r-[3,4,5-3H]leucine and 
L-[4,5-3H]lysine (Amersham Corp.) was added to both cell solu- 
tions and incubated for 5.5  h  at 37~  Cells were washed with 
PBS and class I-associated peptides were isolated as previously de- 
scribed (6). Briefly, pellets were lysed at 107 cells/ml in 2% poly- 
oxyethylene lauryl ether (Sigma Chemical Co.) in  10 mM Tris, 
50 mM NaC1,  pH 7.4, with PMSF, TLCK, and IAA. The post- 
nuclear supernatants were  cleared by  centrifugation for  I  h  at 
100,000 g and applied to affinity columns. Affinity columns were 
packed with  Biogel A15m  beads  (Bio-Rad Laboratories, Her- 
cules,  CA)  coupled to  the  mAbs 4E  or MA2.1.  Bound  class I 
molecules were eluted and denatured by adding 10% acetic acid, 
and  low  molecular weight  species were  separated from  class  I 
heavy chain and ~2m by filtering through a Centricon 10 (Ami- 
con, Beverly, MA). Filtrates were resolved on a reversed-phase 
(RP)  column (p~Bondapak  C18)  using a HPLC  system (Waters 
Chromatography Division, Milford, MA). Gradients were gener- 
ated using an increasing concentration of acetonitrile in 0.1% hy- 
drochloric acid. Flow was 0.5 ml/min and 1.0-ml fractions were 
collected. 
Quantitation of Gel Bands.  The ratio ofendo H-resistant to endo 
H-sensitive forms of class I was determined by exposing the dried 
SDS-PAGE gel to a low intensity phosphorus screen and scan- 
ning by a GS-250 Molecular Imager (Bio-Rad Laboratories). The 
bands  were  quantitated  using  the  program  Molecular Analyst 
Version 2.0.1  (Bio-Rad Laboratories) run on a Macintosh 8100/ 
80 (Apple, Inc., Cupertino, CA). 
Peptide Synthesis and Retention  Times.  Peptides used to deter- 
mine the retention times of HLA-A2 signal sequences were syn- 
thesized  and  purified by  the  Keck  Foundation  Biotechnology 
Resource  Laboratory (Yale University). Retention  times were 
determined by loading and eluting 10 ~g of each peptide individ- 
ually using the column and gradient conditions described above. 
Results 
LLnL Causes a Reversible Accumulation of Ubiquitinated Pro- 
teins.  Ubiquitin-dependent  proteolysis is believed to  be 
the major nonlysosomal proteolytic pathway (30, 31). Ubiq- 
on MHC Class I Peptide Loading Figure  1.  LLnL causes a  re- 
versible accumulation ofubiquit- 
inated  proteins. CIR.B27  cells 
were:  incubated  for  1  h  in 
DMSO alone, washed, and incu- 
bated  for  another  hour  with 
DMSO  (lane  -);  incubated 
with 250 IxM LLnL, washed, and 
incubated again with LLnL (lane 
+);  or  incubated  with  LLnL, 
washed,  and  then  incubated  in 
DMSO  only  (lane +/-).  Cell 
lysates were  separated by  a  5- 
20%  SDS-PAGE  gradient gel 
and  blotted  for ubiquitin  using 
ECL.  (Arrowhead) Position  of 
monomeric ubiquitin. 
uitinated  proteins  are  targeted  for degradation  by the  26S 
protease  complex,  resulting  in  free  ubiquitin  and  peptide 
fragments  (11).  To  confirm  that  inhibition  of the  core  20S 
proteasome of this complex by LLnL disrupts  the degrada- 
tion  of ubiquitinated  proteins,  cell lysates of LLnL-treated 
cells were subjected to SDS-PAGE,  electrophoreticaUy trans- 
ferred  to  an  Immobilon  membrane,  and  probed  with  an 
anti-ubiquitin  serum  (Fig.  1).  In  control  cells,  the  major 
bands were found at ~8  and  14 kD, most likely represent- 
ing ubiquitin and di-ubiquitin,  respectively. However, when 
cells were treated with LLnL, the majority of the anti-ubiq- 
uitin-reactive species migrated in the high molecular weight 
region,  between  97  and  300  kD  (Fig.  1,  center lane).  The 
species  between  97  and  300  kD  presumably  represent  a 
mixture ofubiquitinated  proteins normally degraded by the 
26S protease  complex  (32).  The accumulation  of ubiquiti- 
hated  proteins  was  shown  to  be  reversible.  Cells  washed 
free of LLnL and then  incubated  at 37~  for an additional 
hour (Fig.  t, right lane) exhibited a decrease in high molec- 
ular weight bands. Enhancement of the low molecular weight 
bands  represents  a large pool of newly freed ubiquitin  and 
di-ubiquitin  induced  by LLnL.  These results are consistent 
with the suggestion that a major target of LLnL is the pro- 
teasome. 
LLnL Treatment Slows the Egress of MHC Class I Complexes 
from the ER.  Inhibition  of peptide generation by the pro- 
teasome would be expected to reduce MHC  class I peptide 
loading,  and  consequently,  delay  class  I  transport.  To  ex- 
amine  this,  CllL.A2,  CllL.B7,  and  C1R.B27  cells  were 
incubated  in the presence  or absence of 250  IxM LLnL for 
1 h  at 37~  In the continued presence or absence of inhibi- 
tor, the cells were pulse labeled with [35S]methionine,  chased 
for various times, and extracted in detergent. Class I molecules 
were  immunoprecipitated  with  the  conformation-specific 
antibodies BB7.2  (anti-HLA-A2)  or 4E  (anti-HLA-B).  Af- 
ter treatment with or without  endo H  the immunoprecipi- 
tates  were  subjected  to  SDS-PAGE  and  the  ratio  of the 
endo H-resistant to endo H-sensitive class I molecules was 
quantitated  (Fig. 2, A-C).  Fig.  2 A  shows that almost all  of 
the HLA-A2 molecules had become resistant to endo H  by 
120  rain  in  control  cells.  However,  in  the  presence  of 
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LLnL, the  rate of acquisition  of endo  H  resistance was re- 
duced.  The  amount  of precipitable  HLA-A2  was  also  de- 
creased in cells treated with LLnL, as seen by the decreased 
band intensity.  Both of these findings are consistent  with a 
reduction  in  class  1-associated  peptides.  HLA-A2  cannot 
leave the  EIL until  peptide  has bound,  and  the  amount  of 
stable,  properly  assembled  class  I  molecules  is  decreased. 
Similar  results  were  found  with  HLA-B7  and  HLA-B27 
(Fig. 2, B and  C). 
As a  specificity control,  a  pulse-chase  analysis  of a  non- 
peptide-dependent  molecule,  the  transferrin  receptor,  was 
performed (Fig. 2 D). The transferrin receptor is a dimer of a 
90-kD protein with three  N-linked  glycans.  To accurately 
determine the kinetics of receptor egress from the ElL, bands 
corresponding  to the mobility of glycosylated and nongly- 
cosylated  transferrin  receptor  (filled  and  unfilled  arrow- 
head,  respectively;  Fig.  2)  were  quantitated  at  each  time 
point.  No difference was seen in the rate of transport of the 
transferrin  receptor  with  or without  LLnL.  Similar results 
were  found  for transferrin  receptor  transport  with  the  cell 
line  .174 and other CIR. transfectants  (data not shown). 
LLnL  Treatment  Enhances MHC  Class  I  Association with 
TAP. 1.  Peptide binding  is believed to trigger the release 
of MHC  class  I  molecules from TAP  (2,  3).  To determine 
if the inhibition  ofpeptide generation by LLnL would pro- 
long  the  association  of class  I  HLA  molecules  with  TAP 
proteins, pulsed and chased cells were solubilized in digito- 
nin and the extracts were immunoprecipitated with an anti- 
TAP.1  antibody.  Associated  class  I  molecules  were  re- 
moved by SDS treatment,  reprecipitated  with  an anti-class 
I  heavy  chain  antibody  (3B10.7),  and  separated  by  SDS- 
PAGE.  The  amount  of class  I  associated  with  TAP.1  was 
both enhanced and prolonged in LLnL-treated cells (Fig. 3, 
A-C).  This is most clearly seen at 240 min of chase, where 
almost undetectable  levels of MHC  class  I  molecules were 
TAP  associated  in  control  cells  whereas  clear  bands  were 
present in the LLnL-treated cells. 
LLnL Affects Peptide Association with MHC  Class I Mole- 
cules.  To ascertain ifpeptide association with class  I mole- 
cules was affected by treatment with LLnL, cells were met- 
abolically  labeled  and  the  isolated  peptides  separated  by 
lLP-HPLC.  Fig.  4,  A  and  B  depict  peptides  eluted  from 
HLA-A2. The amount of stable HLA-A2 molecules recov- 
ered  from  cells  treated  with  LLnL  was  decreased  to  less 
than half the amount recovered from control cells. As a re- 
suit,  the  total  yield  of isolated  peptides  was  reduced.  The 
reduction in recovery was not a consequence  of a reduction 
of overall labeling efficiency.  LLnL had no  effect on label- 
ing efficiency under the conditions used. The population of 
peptides bound by HLA-A2 was also qualitatively different 
as  evidenced  by the  general  suppression  of peaks with  the 
exception  of a single peak in fraction numbers  70-74  (Fig. 
4  B). The most dramatic effect on bound peptides was seen 
with  HLA-B7  (Fig.  4,  C  and  D).  In  this  example,  equal 
numbers  of cells were  treated,  and again,  less than  half the 
amount  of class I  molecules  was recovered.  Here the  pro- 
files were  normalized  to  account  for the  difference  in  the 
amounts  of recovered  heavy  chain  and  showed  a  striking Figure 2.  LLnL  slows the transport of MHC class I molecules but not a peptide-independent molecule, the transferrin receptor. Cells were preincu- 
bated for 1 h with 250 p.M LLnL or solvent alone at 37~  pulsed for 15 min with 0.5 mCi of [35S]methionine, and chased for 2 h. Immunoprecipitates 
were treated with endo H and were separated on a 10.5% SDS-PAGE gel. The ratio of endo H-resistant bands to endo H-sensitive bands are shown in 
the respective graphs. Cells and precipitating antibodies are as follows: (A) C1R.A2, BB7.2; (B) CIR..B7, 4E; (C) C1P,.B27, 4E; and (D) C1P,..B7, 1G12 
(control, antitransferrin receptor). Controls (lanes Con) used isotype-matched antibodies. (Filled arrowheads) Endo H-resistant bands; (unfilled arrowheads) 
endo H~ensitive bands. 
enhancement  of peaks  in  fractions  100  and  125  in  the 
LLnL-treated population (note the change in the y-axis). A 
similar  but  less  dramatic  effect  was  seen  for  HLA-B27- 
bound peptides, also normalized for the amount  of recov- 
ered heavy chain (Fig. 4, E  and F). For HLA-B27, as in the 
previous  examples,  peaks  at  75,  90,  and  110  were  en- 
hanced.  The augmentation of a single peak in the presence 
of LLnL  was  also  demonstrated  with  HLA-A3  (data  not 
shown). The peptides that are enhanced by LLnL may rep- 
resent peptides translated at this length in the cytoplasm re- 
quiting no proteolytic cleavage, they may be peptides whose 
generation is unaffected by the inhibitory action  of LLnL, 
or they may be signal sequence  peptides generated in  the 
Elk  whose  generation  is  also  unaffected  by  LLnL.  Both 
HLA-A2 and HLA-B7 have been shown to bind signal se- 
quence-derived peptides (5-7). To determine the origin of 
these  peptides,  it  would  be  necessary  to  sequence  them. 
Unfortunately,  the  time during which  cells can be treated 
with LLnL is hmited to 10 h, after which they begin to die 
(data not shown).  This would make it difficult to accumu- 
late sufficient quantifies of the peptides for sequencing. 
LLnL Inhibits Peptide Generation in the ER.  The  prolonged 
TAP association and slower transport of MHC  class I mole- 
cules in LLnL-treated cells was assumed to result from a reduc- 
tion in the supply of cytosohcally generated peptides. HLA-A2 
in  .174 and T2 cells binds signal sequence peptides, and its 
transport should therefore not be affected by LLnL. Unex- 
pectedly, however, the rate of egress of HLA-A2 from the 
EP, in .174 was found to be greatly diminished in the pres- 
ence of the inhibitor (Fig. 5 A). To determine if the inhibi- 
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HLA-A2  assembly and  transport,  HPLC  profiles  of pep- 
tides bound by HLA-A2 in  .174,  with and without LLnL 
treatment,  were  generated  (Fig.  5  B).  The  major doublet 
Figure 3.  LLnL enhances and extends the association of 
MHC class I molecules with TAP 1. Cells were preincu- 
bated  for 1 h in 250  ~M LLnL or solvent alone at 37~ 
pulsed for 15 min with 2.0 mCi of [3ss]  methionine, chased 
for 4 h and extracted in 1% digitonin.  TAP molecules were 
immunoprecipitated  using purified  anti-TAP. 1 rabbit an- 
tibodies.  Associated class I heavy chains were released by 
SDS  denaturation  and  reprecipitated  using  the  mAb 
3B10.7 (see Materials and Methods).  Cells were as follows: 
(/1) C1R.A2; (B) Cllq..B7;  and (C) C1R.B27. 
peak 3  and the  minor peak  1  were  decreased in the pres- 
ence of LLnL, whereas peaks 2 and 4 were unaffected. These 
peaks, in the cell line T2  (a fusion product of.174 and sim- 
ilarly deficient in TAP  expression), were previously found 
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Figure 4.  LLnL  reduces the amount of assembled  MHC 
class I molecules and changes the profile ofpeptides bound. 
Cells were preincubated with 250  ~M LLnL or solvent 
alone for  1 h at 37~  then labeled with 1 mCi each of 
r-[3,4,5-3H]leucine and L-[4,5-3H]lysine  for 5.5 h. MHC 
class I molecules were isolated by affinity purification and 
the bound peptides were separated by HPLC (see Materials 
and Methods).  Cells and affinity columns  were as follows: 
(A-B) CIR.A2, MA2.1  (peptides loaded  on HPLC were 
not normalized  for class I recovery);  (C-D) CIR.B7, 4E 
(peptides loaded were normalized for class I recovery); and 
(E-F) CIR..B27, 4E (peptides loaded were normalized  for 
class I recovery). 
1573  Hughes et al. to be peptides derived from signal sequence peptides (5, 6). 
The six signal sequence peptides isolated from HLA-A2 in 
T2  were  synthesized,  and  their  retention  times  in  lLP- 
HPLC were determined (Table 1). These peptides included 
fragments of the signal sequences of calreticulin, the ~-inter- 
feron inducible protein (IP-30), and the signal sequence re- 
ceptor ot subunit. The synthetic peptides coeluted with the 
peptides isolated from  .174,  although  the  requirement  for 
collecting fractions to  detect the 3H-labeled peaks made it 
impossible to resolve three of the peptides, which are grouped 
as peak 3 in Fig. 5 and Table 1. However, only peaks 2 and 
4  were  unaffected  by  LLnL.  Peak  2  corresponds  to  the 
longest peptide  (12  residues)  derived from  IP-30  and  ter- 
minates  in  a  COOH-terminal  glutamine  residue.  Peak  4 
corresponds to a part of the calreticulin signal sequence and 
ends in glycine. Peak 1 and all the potential components of 
peak  3  terminate  in  valine or alanine.  Thus  LLnL  in  this 
case may be inhibiting a peptidase with specificity for an al- 
iphatic residue. Because signal sequences are cleaved in the 
ElL, and the TAP deficiency of .174 precludes the reentry 
of peptides into  the ER  after cytosolic trimming, it seems 
most likely that the affected enzyme is an ElL peptidase. 
Cytosolic and ER Proteolysis Have Distinct  Sensitivities  to LLnL 
and Z-LLF-CHO.  To  determine the  relative sensitivities 
of the proteases affecting class I assembly in CllL.A2 and .174 
to LLnL and a more potent proteasome inhibitor (Z-LLF- 
CHO;  20),  we  titrated  their  effects  on  the  intracellular 
transport of HLA-A2 by pulse-chase analysis (Fig. 6). Inhi- 
bition of HLA-A2 transport by LLnL and Z-LLF-CHO  in 
C1R.A2  was  detectable at  2.0  and 0.08  IxM,  respectively 
(Fig. 6, A  and  C).  However,  in  .174,  50.0  I-~M LLnL and 
2.0  ~M  Z-LLF-CHO  were required for an observable ef- 
fect  (Fig.  6,  B  and  D).  These  findings are consistent with 
the idea that the  responsible protease in  CllL and the  re- 
sponsible protease inhibited in  .174  are different, and that 
the protease in CllL, presumably the proteasome, is signif- 
icantly more sensitive. Z-LLF-CHO  was also found to af- 
fect the peptide profile of CIk.B7  in  a  similar fashion  to 
LLnL (data not shown). 
Discussion 
Many studies have  focused on  the  role of the  26S pro- 
tease complex (and its core subunit, the 20S proteasome) in 
Figure  5.  LLnL  slows  HLA-A2  transport 
through  the  Golgi in  the  TAP-negative cell line 
￿9  174 and inhibits the generation of signal sequence 
peptides. 721.174 cells were  preincubated in  250 
IxM LLnL or solvent alone, metabolically labeled 
for 15 min, and chased in the continual presence of 
inhibitor.  (A) HLA-A2 was precipitated from de- 
tergent extracts of the cells harvested at the indi- 
cated times using the mAb BB7.2 and the ratios of 
endo H-resistant to endo H~sensitive class I deter- 
mined; (B) .174 cells were treated with either 250 
mM LLnL or solvent alone and labeled with 1 mCi 
each of L-[3,4,5-3H]leucine  and L-[4,5-3H]lysine  for 
5.5 h. HLA-A2 was isolated using an MA2.1 affin- 
ity column and associated peptides were separated 
by RP-HPLC. 
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1  LLDVPTAAV  IP-30; Wei and Henderson  93.74 
2  LLLDVPTAAVQ  IP-30; Wei  102.76 
3  LLLDVPTAAVQA  IP-30; Henderson  105.43 
LLLDVPTAAV  IP-30; Henderson  107.51 
VLFRGGPRGLLAV  SSRoc; Wei  107.82 
4  MLLSVPLLLG  Calreticulin; Henderson  134.89 
Retention times and source ofHLA-A2-associated  peptides in .174 (see Fig. 5). Indicated references are Wei and Cresswell (6) and Henderson et al. 
(5). 
the generation of class I bound peptides. These studies have 
used LMP7  and LMP2  knockout mice  (14,  15),  cells  ex- 
pressing  a temperature-sensitive  ubiquitinadon phenotype 
(17, 18), and inhibitors of the proteasome (16). Proteasome 
inhibitors, many being peptide aldehydes, have been found 
to inhibit the proteolytic activity of the 20S proteasome in 
vitro (20, 21), to bind to the active site in the crystal struc- 
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uJ 
ture of the 20S proteasome  (19), and to block the genera- 
tion of peptides from cytoplasmic proteins and prevent the 
subsequent expression ofpeptides on the cell surface in con- 
junction with  MHC  class  I  (16).  To  further  characterize 
the effect  of proteasome  inhibitors on the processing  and 
loading of MHC  class I molecules,  we investigated  one of 
the  most  widely  used  cell-permeable  inhibitors,  LLnL. 
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Table  1.  HLA-A2-associated Signal Sequence-derived Peptides 
Synthetic peptide  Peptide source and 
Peak  sequence  reference  Retention time 
[Z-LLF-CHO]  IJ, M 
--  10 
2 
J  0.4 
H---  0.08 
O---  0.0 
Figure 6.  HLA-A2 transport in .174 is less sensitive to both LLnL and Z-LLF-CHO than in the wild-type cell C1R.A2. CIR.A2 (A and C) and .174 
(B and D) cells were preincubated in the indicated concentration ofLLnL (A and/3) or Z-LLF-CHO (C and D), metabolically labeled for 15 n'fin, and 
chased for 2 h in the continued presence of the inhibitor.  HLA-A2 was immunoprecipitated with BB7.2 at the indicated  times and the ratios of endo 
H-resistant to endo H-sensitive class [ determined (see Materials and Methods). 
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class I processing that would result from a peptide-deficient 
state in the  cell.  First,  the rate at which  class I  molecules 
were transported from the ER was slowed in the presence 
of LLnL. Second, the association of class I and TAP mole- 
cules in the El< was enhanced and extended by treatment 
with LLnL. Third, the amount ofpeptides bound by class I 
molecules was  decreased.  LLnL caused  a  reversible accu- 
mulation of ubiquitinated  proteins,  normally degraded by 
the 26S protease complex, lkock et al. (16) showed that the 
ability of a range of peptide aldehyde inhibitors,  including 
LLnL, to inhibit proteasome function, correlated with their 
ability to block MHC class I-restricted antigen processing. 
Thus, although the precise role ofubiquitination in antigen 
processing  remains  in  question,  the  combination  of evi- 
dence strongly argues that the proteasome is the major pro- 
tease involved. 
In addition to reducing the overall yield of MHC class I 
molecules and associated peptides (Fig.  4, A  and B),  LLnL 
also induced changes in the profile ofpeptides bound. This 
is particularly evident in Fig. 4,  C and D, where two HLA- 
B7-associated peaks are dramatically increased.  These and 
similar peaks must correspond to peptides either unaffected 
by LLnL and better represented because of an overall re- 
duction in the available competing pool of peptides, or to 
peptides actively enhanced by LLnL treatment.  For exam- 
ple,  polypeptides  might  normally be  cleaved  within  the 
peptide  sequences  enhanced  in  LLnL-treated  cells.  This 
could occur either in the cytosol, perhaps mediated by the 
chymotryptic-like activity most strongly inhibited by LLnL 
(21),  or even in the Elk after TAP-mediated translocation. 
That  peptide  cleavage  can  occur  in  the  El<  is  clearly 
shown  by  the  effects  of LLnL  on  the  signal  sequence- 
derived peptides associated with HLA-A2 in the TAP-neg- 
ative .174  cell line  (Fig.  5).  LLnL treatment unexpectedly 
slowed the egress of HLA-A2 from the Elk in .174, as did a 
second inhibitor, Z-LLF-CHO (Fig.  6). The inhibitors had 
no  effect on  the  transport  rate  of transferrin  receptors in 
.174 cells,  arguing for an effect specific to class I molecules 
(data not shown).  HLA-A2 escapes the El< in TAP-nega- 
tive  cell  lines  because  it binds  peptides  generated  from a 
number of hydrophobic  signal sequences.  We found  that 
LLnL inhibited the generation of the majority of signal se- 
quence-derived  peptides  that  bind  to  the  HLA-A2  allele 
and propose that the decrease in HLA-A2-specific peptides 
reduces the number of properly assembled, transport-com- 
petent HLA-A2 molecules. Effects on signal sequence deg- 
radation are unlikely to result from proteasome inhibition 
because the proteasome is confined to the cytosol and nu- 
cleus (33). Although evidence exists for an ATP-dependent 
mechanism for peptide  translocation from the  Elk  to  the 
cytosol (34),  any peptides trimmed in the cytosol presum- 
ably would require TAP to reenter the Elk. Thus, in. 174, 
any peptidase involved in generating class I-associated pep- 
tides and affected by LLnL must reside in the ER. The data 
shown in  Fig.  5  B and Table  1 suggest that the peptidase 
inhibited  by  LLnL  may  cleave  COOH-terminal  to  ali- 
phatic amino acids because the unaffected peptides (peak 2 
and  4,  Fig.  5 B) terminate in a glutamate residue and gly- 
cine residue, respectively. However, with the limited num- 
ber ofpeptides available for study it would be premature to 
make this a firm conclusion. 
Transport  of HLA-A2  molecules  was  found  to  be  af- 
fected at lower concentrations  of LLnL and Z-LLF-CHO 
in  Cllk  cells  than  in  .174  cells  (Fig.  6).  Nevertheless,  it 
seems likely that some of the effects of LLnL on class I pep- 
tide loading in wild-type cells could result from inhibition 
of Elk peptidases. When such inhibitors are used to investi- 
gate the  origin  of individual  peptides  that  serve as T  cell 
epitopes,  as  opposed  to  studies  of the  general  process  of 
MHC class I-restricted peptide generation,  this possibihty 
clearly must be borne in mind.  Trimming of certain pep- 
tides in the Elk,  first suggested by Falk et al.  (35)  and for 
which reasonable evidence now exists (36,  37), may be in- 
hibited by LLnL or other peptide aldehyde inhibitors  that 
also inhibit proteasome-mediated degradation.  Even more 
specific  proteasome  inhibitors,  such  as  the  recently  de- 
scribed  Streptomyces-derivative  lactacystin  (38),  must  be 
evaluated for possible effects on Elk-mediated proteolysis 
before their use in antigen-processing studies can be prop- 
erly evaluated. Clearly, inhibitors that specifically affect El< 
peptidases  would  be  extremely useful in  investigating the 
mechanisms involved in generating MHC class I-associated 
peptides. Effects on signal sequence degradation,  measured 
using HLA-A2 in. 174 cells to "trap"the degradation inter- 
mediates as shown in  Fig.  5,  might provide a useful assay 
for such inhibitors. 
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